Skip to Main Content
PFF Help Center
(844) 825-5733
Facebook
LinkedIn
YouTube
Instagram
Join the PFF Registry
Donate
Shop PFF
Menu
Understanding PF
Newly Diagnosed: Start Here
PF Basics: Info for Newly Diagnosed Patients
About Pulmonary Fibrosis
What is Pulmonary Fibrosis?
Causes
Diagnosis
Symptoms
Glossary and Abbreviations
Types of Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Environmental
Occupational
Drug-Induced
Radiation-Induced
Autoimmune Connective Tissue Disease
Other Types of Pulmonary Fibrosis
Treatment Options
Supplemental Oxygen
Pulmonary Rehabilitation
Pulmonary Rehabilitation Toolkit
Symptom Management
Medication
Lung Transplantation
Patients & Caregivers
Medical and Support Resources
Find Medical Care
Find a Support Group
PFF Help Center
Pulmonary Rehabilitation Toolkit
For the Caregiver
Stories from the Heart
Clinical Trials
Medical Statements
Education Resources
Fact Sheets
Maintain Your Health
Videos
Webinars
Telemedicine
Educational Materials
Recursos de fibrosis pulmonar
PFF Insights Blog
Clinical Trials Blog
PFF Summit
Oxygen Therapy
What is Oxygen Therapy?
Benefits
Oxygen Rights and Resources
Oxygen Therapy FAQs
Join a Research Study
PFF Community Registry
APPLe Familial Pulmonary Fibrosis Study
PRECISIONS
Find a clinical trial
Researchers & Healthcare Providers
Clinical Resources
PFF Clinical Resource Hub
Webinars
CME/CE Library
Position Statements
Educational Materials
PFF Summit
Fact Sheets
Research Opportunities
PFF Community Registry
PFF Scholars and Other Research Opportunities
Familial Pulmonary Fibrosis Research Award
PROLIFIC
Community Engagement
Care Center Network
Nurse and Allied Health Network
Host an Event
Book a PFF Ambassador
Request Sponsorship Support
Ways to Give
Ways to Give
Workplace & Matching Giving
Planned Giving
Donor Advised Funds
Donate Stocks & Bonds
Qualified Charitable Distribution (QCD)
Donate Cryptocurrency
Donation FAQs
2026 Tax Law Changes
Albert Rose Legacy Society
Shop PFF
Honor and Memorial Giving
Make a Gift in Honor or Memory
Find a Tribute
Create a Tribute
Fundraising Events
PFF Walk
Broadway Belts for PFF!
Team PFF
Community Walk
Corporate Giving
Corporate Partners
PFF Corporate Committee
Donate Today
Mail-in Donations
Donate Monthly
Get Involved
Events
Attend an Event
Fundraise with Team PFF
Fundraising on Facebook
PFF Walk
PFF Summit 2025
Broadway Belts for PFF!
ILD Day
PFF Education Symposium
Let's Talk Cough
Volunteer
Join the PFF Community Registry
Start a Support Group
Be a PFF Advocate
Share Your Story
Become a PFF Ambassador
PF Awareness Month
Join a Board Committee
Shop PFF
PFF Walk
About the PFF Walk
Bay Area
Chicago
Dallas
National Walk Day
NYC Metro
Pittsburgh
Tampa
Washington, D.C.
Join the PFF Registry
What is the PFF Registry
Getting started
Submit a research proposal
History of the PFF Registry
Registry Report
Meet The Team
Sponsors
FAQ
About Us
Who We Are
Leadership
Mission & History
Medical Advisory Committees
Financials
Our 25 year anniversary
What We Do
The PFF is Me Strategic Plan
Patient Support Programs
Policy & Advocacy
PFF Funded Research
Education
News and Media
News
PFF In The Media
Breathe Bulletin
Media Resources
Careers
Contact Us
Search
Search
External News
Home
External News
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
July 06, 2021
Developing Novel Treatments for Fibrotic Diseases
June 25, 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
May 18, 2021
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
May 18, 2021
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
May 17, 2021
Anti-HSP47 siRNA Lipid Nanoparticle ND-L02-s0201 Reverses Interstitial Pulmonary Fibrosis in Preclinical Rat Models
May 17, 2021
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications
May 17, 2021
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
March 09, 2021
aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
March 09, 2021
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
March 09, 2021
INMARK® results suggest prompt treatment of IPF with antifibrotics to slow disease progression
March 09, 2021
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
March 09, 2021
Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019
March 09, 2021
Pirfenidone improves survival in IPF: results from a real-life study
March 09, 2021
FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States
March 09, 2021
Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
March 09, 2021
Kadmon Presents Data on New ROCK Inhibitor Clinical Candidate at Anti-Fibrotic Drug Development Summit
March 09, 2021
Pliant Therapeutics reports positive results of Phase 1b clinical study supporting advancement of PLN-74809 for treatment of Idiopathic Pulmonary Fibrosis
March 09, 2021
Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis
March 09, 2021
Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis
March 09, 2021
1
2
3
4
5
6
7
8
9
